Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Tenax Therapeutics focuses on addressing cardiovascular and pulmonary diseases with high unmet medical needs. Besides ...

SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $7.08 which represents a slight increase of $0.11 or 1.58% from the prior close of $6.97. The stock opened at $7.02 and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Homeland Security Secretary Alejandro Mayorkas blessed his employees with another three days of taxpayer-funded vacation time, bringing his four-year total to more than six weeks — the ...

Sage Therapeutics, Inc. (SAGE) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session.

Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to acquire the company for $7.22 per share.

While well behind the likes of technology giants such as Amazon, IBM, Microsoft and Google, Tesla in 2024 significantly increased its count of employees hired through the visa program, with its ...